Medtronic plc (NYSE:MDT) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC lessened its position in shares of Medtronic plc (NYSE:MDT - Free Report) by 29.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 166,724 shares of the medical technology company's stock after selling 71,113 shares during the period. Gotham Asset Management LLC's holdings in Medtronic were worth $13,318,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Olstein Capital Management L.P. lifted its holdings in Medtronic by 8.0% during the 4th quarter. Olstein Capital Management L.P. now owns 94,000 shares of the medical technology company's stock worth $7,509,000 after buying an additional 7,000 shares during the last quarter. Czech National Bank lifted its stake in Medtronic by 6.4% during the fourth quarter. Czech National Bank now owns 278,065 shares of the medical technology company's stock worth $22,212,000 after purchasing an additional 16,786 shares during the last quarter. Empowered Funds LLC lifted its stake in Medtronic by 2.7% during the fourth quarter. Empowered Funds LLC now owns 105,822 shares of the medical technology company's stock worth $8,453,000 after purchasing an additional 2,778 shares during the last quarter. Talbot Financial LLC boosted its holdings in Medtronic by 6.4% in the fourth quarter. Talbot Financial LLC now owns 133,453 shares of the medical technology company's stock valued at $10,660,000 after purchasing an additional 8,031 shares in the last quarter. Finally, Caprock Group LLC increased its stake in Medtronic by 12.6% in the fourth quarter. Caprock Group LLC now owns 47,767 shares of the medical technology company's stock valued at $3,849,000 after purchasing an additional 5,363 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Price Performance

Shares of NYSE:MDT opened at $83.47 on Friday. Medtronic plc has a 52 week low of $75.96 and a 52 week high of $96.25. The company has a 50-day moving average price of $86.76 and a 200 day moving average price of $86.79. The company has a market cap of $107.05 billion, a P/E ratio of 25.37, a PEG ratio of 2.22 and a beta of 0.81. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.36 by $0.03. The business had revenue of $8.29 billion during the quarter, compared to analysts' expectations of $8.33 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. Research analysts predict that Medtronic plc will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Friday, March 28th. Medtronic's dividend payout ratio (DPR) is 85.11%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of Medtronic in a report on Wednesday, February 19th. Citigroup raised Medtronic from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $92.00 to $107.00 in a report on Tuesday, March 4th. Truist Financial reduced their target price on Medtronic from $93.00 to $90.00 and set a "hold" rating for the company in a report on Friday, April 11th. Robert W. Baird raised their price target on Medtronic from $90.00 to $91.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $105.00 price objective on shares of Medtronic in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of "Hold" and a consensus price target of $96.14.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.